Learn how Spravato is shaping the future of psychedelic-assisted therapy, including its benefits, research, and impact on modern mental health treatment.
How Spravato is Paving the Way for Legal Psychedelic-Assisted Therapy
In recent years, Spravato has emerged as a groundbreaking option for patients who have not responded to standard therapies. Beyond its immediate benefits, Spravato is helping to shape the future of psychedelic-assisted medicine.
The Psychedelic Renaissance in Medicine
Psychedelics are substances that can significantly alter perception, mood, and thinking. Classical psychedelics, such as psilocybin (found in “magic mushrooms”), LSD, and DMT, produce similar mind-altering effects. Non-classical psychedelics, including MDMA and ketamine, also affect perception and cognition but in different ways than classical psychedelics.
Since the 1960s, scientists have explored how these compounds could support mental health. By shifting perception, psychedelics can help people gain new insights into themselves, their relationships, and patterns of thinking, often opening the door to more positive mental frameworks. However, legal restrictions in the 1980s abruptly halted much of this research, and access to psychedelics became largely limited to illicit use.
Today, however, there is a renewed scientific interest in psychedelics as treatments for mental health conditions, including depression, anxiety, and PTSD. Clinical trials have demonstrated that, when used in controlled settings, psychedelics can be safe and effective for reducing symptoms.
This resurgence of research, often called the “psychedelic renaissance,” is laying the groundwork for new, evidence-based therapies.
What is Spravato?
Spravato is a prescription nasal spray containing esketamine, a compound derived from ketamine. Like ketamine, Spravao has a unique mechanism of action compared to antidepressants and offers rapid relief for patients who don’t respond to these traditional medications.
Spravato was FDA approved for patients with treatment-resistant depression (TRD) in 2019, and major depression with suicidal ideation (MDSI) one year later. Like ketamine, it has psychoactive properties and may be categorized as a non-classical psychedelic. As such, it could be considered a prototype for the legalisation of other psychedelic therapies. Spravato is also helping reduce stigma about using psychoactive compounds in psychiatry.
Spravato as a Non-Classical Psychedelic
While Spravato differs from classical psychedelics, it shares certain mind-altering qualities. Its primary psychoactive effect is dissociation, which is a feeling of separation from one’s body or surroundings.
The term psychedelic originally came from psychiatrist Humphrey Osmond, who was researching LSD and mescaline in the 1960s. He coined the term based on the Greek words psyche and deloun, which roughly translates to “mind” and “to-reveal.” In line with this definition, Spravato users have highlighted that the drug helps bring up repressed memories and emotions.
Moreover, like classical psychedelics, Spravato also appears to increase cognitive flexibility - the brain’s ability to shift thinking patterns and consider alternative solutions. This flexibility is a key mechanism for depression treatment, as it can help patients break free from rigid, negative thought patterns associated with depression.
How Spravato Helps Inform Psychedelic Medicine
According to Johnson & Johnson, the company that developed Spravato, over 100,000 U.S. residents have been treated with Spravato under controlled conditions. Long-term studies show that the medicine is both relatively safe and efficacious for considerable numbers of patients with TRD and MDSI. A recently published study followed 20 patients for an average of 2.5 years and found 85% of patients improved in depressive severity, with 25% achieving remission and no-one experiencing serious adverse effects.
The success of Spravato offers valuable insights for the broader field of psychedelic medicine. It demonstrates how structured protocols and medical oversight can transform psychoactive compounds into viable, clinically acceptable treatments.
Lessons for Future Psychedelic Therapies
The positive outcomes from Spravato highlights several important lessons for the future of psychedelic medicine.
- Rigorous Testing
Spravato’s development involved many clinical trials, helping ensure its effectiveness and safety. For other psychedelic medicines to be approved, they will need to undergo rigorous testing.
- Standardized Models with Additional Services
Spravato treatment follows a standardized model, with trained clinical staff supervising patients during the session and for two hours afterward. This careful monitoring helps manage side effects and ensures patients feel safe and supported throughout the experience. In the broader context of psychedelic therapies, having a standardized, safety-focused model is essential for developing new treatments
- Additional Services
While all clinics are required to follow guidelines, some go further to help patients maximize the benefits of treatment. At ReYou in New Jersey, for example, we offer integration services, personalized therapeutic support designed to help patients process insights and apply them to daily life.
Additional support services can make psychedelic therapies more tailored and effective, addressing each patient’s unique needs.
- Exclusion Criterion
While Spravato can be a powerful option for many patients, it is not suitable for everyone and there are clear guidelines about who can and can’t access treatment. Psychedelic therapies should also have clear exclusion criteria to prevent serious side effects in patients who are at a greater risk. The criteria will be different for different substances as they have different physiological effects.
- Insurance Coverage
Access to therapy with classical psychedelics is currently very limited, and when available, it can be extremely expensive. Services can cost thousands of dollars per session. Spravato, by contrast, is widely recognized by major insurance providers, so treatment costs are often covered for patients who meet the clinical criteria. If classical psychedelics are eventually approved for mental health use, insurance coverage could make these therapies far more accessible to a broader range of patients.
Experience the Benefits of Spravato at ReYou in New Jersey
At ReYou, we are proud to be a leading provider of Spravato treatments in New Jersey. Our approach blends the clinical rigor of standardized Spravato protocols with the holistic principles of psychedelic-assisted therapy. We focus on addressing the root causes of depression, supporting emotional processing, and maximizing long-term benefits for our patients.
If you or a loved one are struggling with TRD, ReYou can help determine if Spravato therapy is right for you. Contact us today to learn more about our programs and take the first step toward a renewed sense of mental wellbeing.
